Lilly's Oral Weight-Loss Pill Gets FDA Nod; Tariff Threat

Major FDA approval for obesity treatment as Trump administration eyes pharma tariffs

Healthcare Market Overview

$UNH has declined 46.2% over one year but received an upgrade from Raymond James suggesting a potential rebound opportunity at $273.98. The Trump administration is set to announce tariffs as soon as Thursday on drugmakers that have not struck deals guaranteeing low prices in the U.S., according to Bloomberg News. Biotech is experiencing a comeback year in 2026 as headwinds in the sector clear.

Big Pharma & Biotech

$LLY shares jumped 4.7% after the FDA approved Foundayo (orforglipron), its highly anticipated once-daily oral weight-loss pill. $MRK announced positive Phase 3 CORALreef AddOn trial results on March 30 for enlicitide decanoate, an investigational once-daily oral PCSK9 inhibitor. $JNJ struck a $500 million research and development agreement with Royalty Pharma on March 30 to support an experimental antibody treatment for autoimmune diseases. $GILD extended its tender offer to acquire Arcellx at $115.00 per share plus a $5.00 CVR.

MedTech & Devices

$ABT invested in Whoop's $575 million Series G funding round as a strategic participant, linking the company's medical device and diagnostics expertise with Whoop's health wearable platform. The investment highlights Abbott's interest in digital health wearables and consumer-facing health data solutions. $ISRG appeared in featured analyst reports showing mixed momentum.

FDA & Regulation

$LLY received FDA approval for Foundayo, marking a significant milestone in the obesity treatment market with the first once-daily oral option. $ABBV presented a broad slate of dermatology data at the 2026 American Academy of Dermatology meeting, including long-term results for Skyrizi and Rinvoq, as well as a new FDA label update. The Trump administration is preparing new tariffs on select drugmakers that have not agreed to low-price guarantees.

Looking Ahead

Investors will monitor the implementation timeline and scope of potential tariffs on pharmaceutical companies as the Trump administration moves forward with pricing pressure initiatives. $MRK's Tempus AI collaboration has expanded following new data from the ALERT cardiology trial, though the company's stock has shown fading momentum with a one-year total shareholder return decline of 27.49%. Dermatology data presentations continue at the American Academy of Dermatology meeting.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy